These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18520303)

  • 1. K-ras as a target for lung cancer therapy.
    Adjei AA
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S160-3. PubMed ID: 18520303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discussion - EGFR-targeted agents.
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S150-1. PubMed ID: 18520301
    [No Abstract]   [Full Text] [Related]  

  • 3. K-ras as a target for cancer therapy.
    Friday BB; Adjei AA
    Biochim Biophys Acta; 2005 Nov; 1756(2):127-44. PubMed ID: 16139957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Riely GJ
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S146-9. PubMed ID: 18520300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in lung cancer: clinical developments and future directions.
    Blumenschein G
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Targeting KRAS pathway in NSCLC therapy].
    Le Moulec S; Loriot Y; Soria JC
    Bull Cancer; 2009 Dec; 96 Suppl():S69-74. PubMed ID: 20034872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
    Silvestri GA; Rivera MP
    Chest; 2005 Dec; 128(6):3975-84. PubMed ID: 16354869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
    Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
    Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
    Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
    Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
    Toyooka S; Uchida A; Shigematsu H; Soh J; Ogino A; Takata M; Kiura K; Ouchida M; Kosaka T; Aoe M; Mitsudomi T; Date H
    J Thorac Oncol; 2007 Apr; 2(4):321-4. PubMed ID: 17409805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 12. Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
    Zhang X; Chang A
    J Med Genet; 2007 Mar; 44(3):166-72. PubMed ID: 17158592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
    Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
    Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gefitinib as targeted treatment for non-small-cell lung cancer].
    Knuuttila A; Karjalainen EM; Rouhos A; Mali P
    Duodecim; 2005; 121(3):267-72. PubMed ID: 15787284
    [No Abstract]   [Full Text] [Related]  

  • 16. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
    Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients.
    Tsao DA; Yang MJ; Chang HJ; Yen LC; Chiu HH; Hsueh EJ; Chen YF; Lin SR
    Lung Cancer; 2010 Apr; 68(1):51-7. PubMed ID: 19589613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.